	US 11,873,336 B2
	Heavy chain antibodies binding to CD22
Shelley Force Aldred, Thousand Oaks, CA (US); Wim van Schooten, Thousand Oaks, CA (US); Heather Anne N. Ogana, Thousand Oaks, CA (US); Laura Marie Davison, Thousand Oaks, CA (US); Katherine Harris, Thousand Oaks, CA (US); Udaya Rangaswamy, Thousand Oaks, CA (US); and Nathan D. Trinklein, Thousand Oaks, CA (US)
Assigned to TENEOBIO, INC., Thousand Oaks, CA (US)
Appl. No. 16/956,502
Filed by TeneoBio, Inc., Thousand Oaks, CA (US)
PCT Filed Dec. 21, 2018, PCT No. PCT/US2018/067299 § 371(c)(1), (2) Date Jun. 19, 2020, PCT Pub. No. WO2019/126756, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/609,759, filed on Dec. 22, 2017.
Prior Publication US 2021/0095022 A1, Apr. 1, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01)]

14 Claims

1. A heavy chain-only antibody binding to CD22 comprising a heavy chain variable region comprising:

(a) a CDR1 sequence of any one of SEQ ID NOs: 2-10; and

(b) a CDR2 sequence of the formula:

X7 X8 Y X9 G X10 X11

where X7 is I or V;

X8 is Y or H;

X9 is S or T;

X10 is A, V or S; and

X11 is T or A; and

X12 R X13 D S S X14 W R S

where X12 is T, A or K;

X13 is D or E; and

X14 is N or S.